Abstract:Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for over 80% of all the lung cancer cases. The application of advanced gene sequencing technology has identified several specific driver genetic mutations in NSCLC, such as EGFR, KRAS and EML4-ALK etc. The most common types of EGFR activating mutation are L858R substitution mutation on exon 21 and in-flame deletion mutation on exon 19. It leads to the high demand of using small molecule tyrosine kinase inhibitors specific to these mutations as a new anti-cancer strategy. For example, Gefitinib is used for treating NSCLC with EGFR activating mutation. Despite the great achievement in the initial response of Gefitinib treatment, drug resistance remains an unresolved problem. The discovery of new inhibitors or drugs targeting the molecules responsible to Gefitinib resistant is urgent needed. The application of natural products to achieve therapeutic properties has been tried for a long time along human civilization. Plants, animals and mineral products are the main sources of the natural drugs. In this study, we have found a single compound, designated as MUST-1, which is purified from a Chinese medicine herb, is a potential anti-cancer compound in Gefitinib resistant NSCLC. MUST-1, which is a natural alkaloid, is isolated from a commonly used Chinese medicinal herb, which has been utilized clinically to treat inflammatory diseases, anti-microbe, anti-inflammation and anti-oxidation functions traditionally. Quantitative analysis using flow cytometer of the control and the MUST-1-treated cells after Annexin V/PI staining showed that MUST-1 significantly induced apoptosis in NSCLC cells after 24 hours treatment, the effect is especially effective in those NSCLC cell lines with EGFR mutation(s) and resisted to Gefitinib treatment. Western blot analysis demonstrated that MUST-1 initially activated c-Jun-N-terminal kinase (JNK) and p38 phosphorylation, triggered EGFR degradation and suppressed the EGFR downstream anti-apoptotic AKT signaling. Moreover, NF-κB pathway suppression was also observed. JC-1 staining was used to prove the change in mitochondrial membrane potentials, our result showed that mitochondrial disruption plays an important role in the MUST-1-mediated apoptosis. Further Western blot analysis showed that Caspases-3/7 was activated during apoptosis. Treatment with pan-caspases inhibitor can attenuate the apoptotic effect of MUST-1, suggesting that apoptosis induced by MUST-1 is Caspases-dependent. Overall, our data suggest that MUST-1 is particularly effective in Gefitinib-resistant NSCLC. It may potentially be developed as an alternative treatment option for the NSCLC patients who have developed Gefitinib resistance. Citation Format: Xing-Xing Fan, Maria Pik Wong, Zhi-Wei Cao, Na Li, Jin-Lin Wu, Hua Zhou, Zhi-Hong Jiang, Liang Liu, Elaine Lai-Han Leung. Apoptotic effect of a single compound derived from natural product in Gefitinib-resistant non-small cell lung cancer cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3193. doi:10.1158/1538-7445.AM2014-3193

1‑O‑acetylbritannilactone combined with gemcitabine elicits growth inhibition and apoptosis in A549 human non‑small cell lung cancer cells

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells.

Preclinical Development Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP 9 X and Mcl-1

The killing effect of rmhTNF-α combined with gemcitabine on human lune adenocarcinoma cells A549

Data from Synergistic Antitumor Activity of Gemcitabine and ABT-737 <i>In Vitro and In Vivo</i> through Disrupting the Interaction of USP9X and Mcl-1

ABL-N-induced Apoptosis in Human Breast Cancer Cells is Partially Mediated by C-Jun NH2-terminal Kinase Activation

Acetylbritannilactone suppresses growth via upregulation of krüppel-like transcription factor 4 expression in HT-29 colorectal cancer cells.

Alantolactone Enhances Gemcitabine Sensitivity of Lung Cancer Cells Through the Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress and Akt/GSK3β Pathway

ABL‐N Induces Caspase‐dependent Apoptosis in Human Breast Cancer Cells Via Activation of C‐jun‐nh2‐terminal Kinase

A potential anticancer agent 1,2-di(quinazolin-4-yl)diselane induces apoptosis in non-small-cell lung cancer A549 cells

Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer

Abstract 3193: Apoptotic Effect of a Single Compound Derived from Natural Product in Gefitinib-resistant Non-Small Cell Lung Cancer Cells

The Apatinib and Pemetrexed Combination Has Antitumor and Antiangiogenic Effects Against NSCLC

Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells

Acetylbritannilactone is a Potent Synergist of Celecoxib to Inhibit Cyclooxygenase‐2 Expression and to Induce Apoptosis in Human Breast Cancer Cells

Inhibiting nonhomologous end-joining repair would promote the antitumor activity of gemcitabine in nonsmall cell lung cancer cell lines

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway

Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells